Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Apexbio Technology LLC Dabrafenib Mesylate (GSK-2118436) 1195768-06-9 10mg
Supplier: Apexbio Technology LLC A334710
Dabrafenib Mesylate (GSK-2118436 CAS 1195768-06-9) is a potent orally active inhibitor that specifically targets the mutant BRAF kinase variant V600E BRAF functions as a serine/threonine kinase essential in the MAPK/ERK signaling cascade frequently mutated in various human cancers Dabrafenib selectively inhibits BRAF V600E (IC50 0 8 nM) with lower activity against wild-type B-Raf and c-Raf By binding and disrupting BRAF V600E activity dabrafenib attenuates downstream MAPK/ERK activation leading to reduced cellular proliferation and tumorigenicity This agent is useful for investigating oncogenic pathways and was FDA-approved for metastatic melanoma with BRAF V600E mutation
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?